Dengue virus (DENV), the causative agent of dengue fever (DF), is one of the most important mosquito-borne viruses that can infect humans. Although much effort has been made on prevention and control of dengue, there are currently no anti-viral drugs or worldwide approved vaccines yet. In this study, we immunized six-week-old Balb/c mice with DNA vaccine candidates E and NS1-2a of DENV serotype 2 or the combination of them (E+NS1-2a) via an electroporation (EP)-assisted intramuscular gene delivery system and evaluated the immune response and protection. The highest specific antibody titres and cytokine levels secreted by splenocytes as well as the highest survival rate were observed in the E+NS1-2a group, followed by E group and NS1-2a group. Our data suggested that the combination of E and NS1-2a delivered by EP may be a superior preventive strategy against DENV.
titres were detected by plaque assay using Vero cell monolayer under 1.2% methyl cellulose.
Construction and identification of plasmids
E (from 877 to 2421bp) and NS1-2a (from 2388 to 4131bp) genes were amplified from DENV2-infected C6/36 cells by PCR, and the primers were listed in Table 1 . The genes were constructed in the vector pReceiverM01 and were named pRe/E and pRe/NS1-2a. The recombinant plasmids were identified by sequence analysis (Sangon Biotech Co., Ltd., Shanghai, China) and the expression of the proteins was confirmed by indirect immunofluorescence (IFA) [19] . In brief, plasmids were transfected into Vero cells by Lipofectamine 2000 (Invitrogen, California, USA). At 24h after transfection, the cells were fixed with 4% polyformaldehyde and permeabilized by 0.2% Triton X-100. After washing and blocking, the cells were incubated with monoclonal anti-DENV2 E or NS1 antibody (Abcam, Tokyo, Japan) at 4°C overnight. Then, the cells were incubated with FITC-conjugated goat anti-mouse IgG (Earthox, San Francisco, USA). The results were analysed by fluorescent microscope (Olympus, Japan). 
Immunization and challenge experiments in mice
The 6-week-old Balb/c mice were divided into 4 groups (20 mice for each group): E, NS1-2a, E+NS1-2a, and pReceiverM01 groups. Mice were inoculated with E (50μg) or NS1-2a (50μg) or mixture of E and NS1-2a (50μg for each) through EP. Briefly, after injection using a syringe with a 25-27 gauge needle, two silver electrodes (6mm apart) were immediately inserted the injection site bilaterally, and six electric pulses (36V, 10ms) were applied by a gene delivery device (Terasa Healthcare Sci-Tech, China). Mouse immunized with 50μg of pReceiverM01 served as a control.
Three weeks after the final immunization, 6 mice in each group were euthanized for collecting sera and spleen samples to evaluate the humoral and cellular immunity. The other 14 mice were intracerebrally (i.c.) injected with a lethal dose (50LD50) of DENV2 using a 27-gauge one-stop needle (Top Injection Needle, Tokyo, Japan). These mice were monitored daily, and the morbidity and mortality was evaluated for three weeks. Clinical symptoms were scored as follows: 0: healthy; 1: ruffled hair; 2: hunchbacked appearance; 3: bradykinesia; 4: paralysis; and 5: death.
Antibody assay by enzyme-linked immunosorbent assay (ELISA)
Mouse serum samples were collected by tail-bleeding three weeks after the final immunization, and the antibodies against DENV2 were evaluated using ELISA as described previously [19] .
Briefly, 96-well microtiter plates were coated with 5μg of concentrated DENV2 protein as the antigens. 100µl of two-fold serial dilutions of the serum samples were added to each well. After washing with 0.05% Tween-20 in Phosphate Buffered Saline (PBS-T), the plates were incubated with goat anti-mouse IgG-horseradish peroxidase (HRP) (1:3000, KPL, USA) at 37°C for 1h, followed by addition of the orthophenylenediamine substrate solution for visualization. The reactions were stopped by addition of 2M H 2 SO 4 . The absorbance was measured at 492nm with a microplate reader (Multiskan, Mk3, Thermo, USA). The end-point titres of the serum samples were determined as the reciprocal of the highest dilution, giving an optical density (OD) twice that of the non-immune serum. End-point titres of anti-DENV2 antibodies were recorded as geometrical mean titres (GMT). To determine the IgG subclass, antibody isotype ELISAs were performed, in which anti-mouse IgG-HRP was replaced with anti-mouse IgG1-HRP or anti-mouse IgG2a-HRP (BD PharmingenTM, USA).Values of IgG subclasses were reported as the mean ± SD of the OD at 492nm at a serum dilution of 1:400.
Cytokine ELISPOT assays
Three weeks after the final vaccination, splenocytes were isolated by mouse lymphocyte separation medium (DAKEWEI, Beijing China), and the production of IFN-γ, IL-2, IL-4, and IL-10 were measured using an ELISPOT assay according to the manufacturer's instructions (BD Biosciences, USA) [20] . Briefly, 96-well filtration plates (Millipore, Bedford, USA) were pre-coated with anti-mouse IFN-γ, IL-2, IL-4 or IL-10 antibodies, and then 1×10
Results

The recombinant plasmids efficiently expressed in eukaryotic cells
To test the expression of the recombinant plasmids pRe/E and pRe/NS1-2a in eukaryotic cells, plasmid DNA was transfected into Vero cells, and IFA was performed. As shown in Figure 1 
Antibody response to immunizations
Three weeks after the final immunization, serum samples were collected for determining anti-DENV2 antibody levels. As expected, the mice inoculated with E, NS1-2a or E+NS1-2a
showed increasing end-point titres of anti-DENV2 IgG compared with the control group (pReceiverM01, P< 0.01). Of those, the E+NS1-2a group showed the highest anti-DENV2 antibody titres, with a GMT of 1:9051, while antibody titres in the NS1-2a and E groups were 1:800 or 1:3200, respectively (Figure 2. ). These results suggested that our DNA vaccine candidates could induce effective immune responses against DENV2. Levels of anti-DENV2 IgG1 and IgG2a were also detected, and results were shown in Figure 3 .. Both IgG1 and IgG2a increased in all the groups compared to the control group. But there were some differences among these groups: in E group IgG2a titre was higher than IgG1 (p<0.05) with significantly increased IgG2a/IgG1 ratio, which showed unconspicuous change in NS-2a and E+NS1-2a groups. Interestingly, the obviously increased IgG1 level was observed in the E+NS1-2a group compared with that in E group (P<0.05) (Figure 3. ). The results indicated that different immune response biases were induced by our DNA vaccine candidates, which express different immunogens and may be linked to the protective efficacy. Mouse serum samples were collected three weeks after the final immunization, and the antibodies against DENV2 were evaluated by ELISA. The end-point titres in serum samples were determined as the reciprocal of the highest dilution, giving an optical density (OD) value twice that of the non-immune serum from control mice. The bar graph shows the geometrical mean standard deviation (SD) values for all the groups (n=6) (*p<0.05; **p<0.01, one-way ANOVA test). Antigen-specific ELISA is reported as the OD values at 492nm at a serum dilution of 1:400. The bar graph shows the mean SD values for OD values of all the groups with plasmids (*p<0.05; **p<0.01, one-way ANOVA test).
Generation of cytokines in the plasmid-immunized mice
Cytokines play a crucial role in the induction and modulation of the immune responses. The levels of cytokines secreted by splenocytes of immunized mice upon stimulation with the DENV2 high levels of anti-DENV2 antibodies and cytokines as well as good protection against DENV2 challenge were found in mice immunized with E+NS1-2a, indicating that E+NS1-2a via electroporation is effective way for prevention of DENV infection.
Two factors were considered to contribute the effective protection in this study. We think that the first important one is the immunogens used in the experiment. Dengue E protein contains the most important neutralizing antigenic sites, and antibodies against E protein can neutralize the same serotype of DENV and block the infection. NS1 protein, the only non-structural glycoprotein expressed on the cell surface, is secreted in patient serum and can invoke an immune response and confer protection in animals by ADCC without the adverse effects of ADE [25] . In this study, E and NS1-2a were used separately or in combination and the characterization of immune responses induced by these two proteins showed some differences: in E group, the IgG2a levels were higher than the IgG1 levels (P<0.01) and all tested cytokines increased while the NS1-2a induced an Next, effective immunity induced by E+NS1-2a should owe to EP delivery system. It is known that EP transiently creates pores in the myocyte membranes and then effectively enhances the cellular uptake of plasmids, which dramatically affects the magnitude of the immune responses. It was reported that DNA vaccines have been less efficient and limited protection in larger animal models, even at multiple immunizations and high DNA doses. However, our recent study demonstrated that elevated expression of the prME protein was observed in EP-administered mice and rabbits [11] , and higher levels of specific IgG and neutralizing antibody were also successfully induced. It suggested that EP may circumvent the barrier, raise transfection efficiency and internalization and substantially elevate the potency of DNA vaccines and enhance immune protection. Taken together, our results suggested that a combination of E and NS1-2a may be a novel strategy against DENV infection and EP may be the inspiring gene delivery strategy in DNA vaccine development.
